Department of Research, Centre d'Higiene Mental Les Corts, c/Numància 103-105 baixos, 08029, Barcelona, Spain.
Qual Life Res. 2011 Sep;20(7):1079-89. doi: 10.1007/s11136-011-9847-1. Epub 2011 Feb 3.
The World Health Organization Quality of Life Scale Brief Version (WHOQOL-BREF) is used for patients with schizophrenia although no validation is available. This work addresses this issue by dealing with its psychometric properties in a clinical sample of patients with schizophrenia.
Two hundred forty-one patients from 10 Adult Mental Health Care Centers (AMHCC) meeting the following inclusion criteria were included: (1) International Classification of Diseases-10 or ICD-10 diagnosis of schizophrenia, (2) Global Assessment of Functioning scores or GAF ≤ 50, 3) Illness duration of more than 2 years and (4) Clinical stability at assessment time. Patients were evaluated at baseline and at one-year follow-up regarding quality of life (QOL), clinical variables and other psychosocial measures.
Internal consistency was excellent for the total WHOQOL-BREF (0.88 at baseline and 0.89 at follow-up) and adequate (0.65-0.78 at baseline; 0.66-0.79 at one-year follow-up) for the WHOQOL-BREF domains. Correlations between WHOQOL-BREF scores and those of global functioning, psychiatric symptoms, disability and social support ranged between small and large. There were significant differences between groups of patients with schizophrenia in the WHOQOL-BREF. Patients who were anxious, disabled, lacked social support and used more social services scored significantly lower in some or all WHOQOL-BREF domains. Changes in WHOQOL-BREF scores were positively associated with changes over time in global functioning, social support and use of health services, and negatively with psychiatric symptoms and disability (correlation coefficients between small and moderate). After one-year follow-up, patients improved in overall functioning and there was a decrease in psychiatric symptoms.
This study shows that the WHOQOL-BREF has good reliability and validity, and suggests that it is suitable for the assessment of QOL in patients with schizophrenia.
世界卫生组织生活质量量表简表（WHOQOL-BREF）用于精神分裂症患者，尽管尚未验证其有效性。本研究通过对精神分裂症患者的临床样本进行心理测量学特性分析来解决这一问题。
从 10 家成人精神卫生保健中心（AMHCC）中纳入符合以下纳入标准的 241 名患者：（1）国际疾病分类第 10 版或 ICD-10 诊断为精神分裂症，（2）总体功能评估分数或 GAF≤50，（3）患病时间超过 2 年，（4）评估时病情稳定。患者在基线和 1 年随访时接受生活质量（QOL）、临床变量和其他社会心理测量评估。
WHOQOL-BREF 总量的内部一致性非常好（基线时为 0.88，随访时为 0.89），各分量表的内部一致性在可接受范围内（基线时为 0.65-0.78，随访时为 0.66-0.79）。WHOQOL-BREF 评分与总体功能、精神症状、残疾和社会支持之间的相关性在小到大之间。精神分裂症患者组之间在 WHOQOL-BREF 上存在显著差异。焦虑、残疾、缺乏社会支持和使用更多社会服务的患者在某些或所有 WHOQOL-BREF 分量表中得分显著较低。WHOQOL-BREF 评分的变化与总体功能、社会支持和卫生服务利用随时间的变化呈正相关，与精神症状和残疾呈负相关（相关系数在小到大之间）。经过 1 年随访，患者的整体功能得到改善，精神症状有所下降。
本研究表明，WHOQOL-BREF 具有良好的信度和效度，适用于评估精神分裂症患者的生活质量。
